Contact

Our portfolio

Haermonics

Innovating post-surgery care, Haermonics develops a device to flush and clean the pericardial space, preventing blood-related complications after open-heart surgery. Their technology reduces the risk of blood clots and subsequent operations. The company is dedicated to improving surgical outcomes through advanced medical devices.

  • Institute: Amsterdam UMC
Industry: Cardiology, Medical Technology, Surgery
  • Founding year: 2015
Visit website

Want to get in contact about Haermonics?

We’re happy to connect. Reach out to our investment manager working with the team to learn more or explore potential opportunities.

Browse all investment managers

Marc Roelofs

Life Science & Health

Our portfolio

Check out similar ventures

Sightcorp
Specializing in AI-powered audience intelligence, Sightcorp provides automated facial analysis and emotion recognition technology.
DCPrime
Pioneering cancer vaccines, DCPrime leverages its DCOne® dendritic cell technology to develop innovative immunotherapies.
InspectT
Enabling standard spectrometers to simultaneously measure both chemical composition and particle size by integrating patented, cost-effective Optical-DOSY flow cells.

GuanaRep

GuanaRep
Repurposing the obsolete hypertension drug Guanabenz for the treatment of Vanishing White Matter.
Sightcorp
Specializing in AI-powered audience intelligence, Sightcorp provides automated facial analysis and emotion recognition technology.
DCPrime
Pioneering cancer vaccines, DCPrime leverages its DCOne® dendritic cell technology to develop innovative immunotherapies.
InspectT
Enabling standard spectrometers to simultaneously measure both chemical composition and particle size by integrating patented, cost-effective Optical-DOSY flow cells.

GuanaRep

GuanaRep
Repurposing the obsolete hypertension drug Guanabenz for the treatment of Vanishing White Matter.
Explore full AAV portfolio
Contact